Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

10X Genomics Inc (TXG)

10X Genomics Inc (TXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,296,937
  • Shares Outstanding, K 126,553
  • Annual Sales, $ 610,790 K
  • Annual Income, $ -182,630 K
  • EBIT $ -91 M
  • EBITDA $ -48 M
  • 60-Month Beta 2.15
  • Price/Sales 3.70
  • Price/Cash Flow N/A
  • Price/Book 2.88

Options Overview Details

View History
  • Implied Volatility 73.23% (-1.54%)
  • Historical Volatility 82.35%
  • IV Percentile 19%
  • IV Rank 29.10%
  • IV High 127.16% on 04/23/25
  • IV Low 51.09% on 08/21/25
  • Expected Move (DTE 14) 1.36 (7.65%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,514
  • Volume Avg (30-Day) 1,243
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 10,813
  • Open Int (30-Day) 14,072
  • Expected Range 16.41 to 19.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 8
  • High Estimate -0.13
  • Low Estimate -0.27
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.80 +38.83%
on 11/06/25
20.34 -12.64%
on 11/25/25
+4.28 (+31.73%)
since 11/05/25
3-Month
11.16 +59.23%
on 10/14/25
20.34 -12.64%
on 11/25/25
+3.81 (+27.29%)
since 09/05/25
52-Week
6.78 +162.09%
on 04/07/25
20.34 -12.64%
on 11/25/25
+2.54 (+16.68%)
since 12/05/24

Most Recent Stories

More News
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know

BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know

FTRE : 14.24 (-1.79%)
MEDP : 548.12 (+0.61%)
TXG : 17.77 (-2.09%)
BTSG : 35.79 (+1.79%)
QDEL : 27.76 (-0.22%)
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know

Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know

TXG : 17.77 (-2.09%)
PACB : 2.39 (-5.16%)
BRKR : 48.03 (-0.72%)
XRAY : 11.25 (-0.18%)
ICUI : 142.51 (+0.11%)
3 Reasons to Avoid TXG and 1 Stock to Buy Instead

3 Reasons to Avoid TXG and 1 Stock to Buy Instead

TXG : 17.77 (-2.09%)
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region

TXG : 17.77 (-2.09%)
1 Momentum Stock with Promising Prospects and 2 We Avoid

1 Momentum Stock with Promising Prospects and 2 We Avoid

TXG : 17.77 (-2.09%)
ILMN : 128.96 (+0.73%)
PH : 880.00 (+0.73%)
5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call

5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call

TXG : 17.77 (-2.09%)
1 Small-Cap Stock for Long-Term Investors and 2 We Avoid

1 Small-Cap Stock for Long-Term Investors and 2 We Avoid

TXG : 17.77 (-2.09%)
OSCR : 16.77 (-2.39%)
SGRY : 17.19 (-1.09%)
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025

PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate...

TXG : 17.77 (-2.09%)
Why 10x Genomics (TXG) Stock Is Trading Up Today

Why 10x Genomics (TXG) Stock Is Trading Up Today

TXG : 17.77 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

10x Genomics Inc. is a life science technology company. It develops and sells instruments, consumables and software for analyzing biological systems. 10x Genomics Inc. is based in Pleasanton, California.

See More

Key Turning Points

3rd Resistance Point 18.99
2nd Resistance Point 18.60
1st Resistance Point 18.18
Last Price 17.77
1st Support Level 17.37
2nd Support Level 16.98
3rd Support Level 16.56

See More

52-Week High 20.34
Last Price 17.77
Fibonacci 61.8% 15.16
Fibonacci 50% 13.56
Fibonacci 38.2% 11.96
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar